ClinicalTrials.gg
CompletedNCT06898047CORRELATE-UKUpdated Nov 19, 2026

Consistency of Response With Rimegepant in Acute Treatment of Migraine

An observational study in Migraine, sponsored by Pfizer. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Pfizer · Observational

How we know

Updated Nov 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Migraine Disorders by Pfizer — 10 open to participants now, 13 under way, 6 of them phase 3. Migraine Disorders · Pfizer.

Started
2025
with 3 others
Observational
9 of 47
2 open now
Registered
40th of 47
by date

Among the 47 studies in Migraine Disorders by Pfizer, this one is one of 4 that started in 2025, is one of 9 observational ones, and was the 40th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

10 of the 47 studies in Migraine Disorders by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Migraine Disorders by Pfizer, or all of them as a file.
02

Study summary

This is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks. Participants will be followed up for up to 12 weeks and will complete a daily questionnaire to self-report the consistency of response to rimegepant in acute treatment of migraine.

Read the detailed description

This is a prospective observational, real-world cohort study of the patient-reported consistency of response to rimegepant in acute treatment of migraine. Longitudinal data capture will allow the determination of treatment effectiveness across multiple attacks, while the observational design will ensure the data reflect a real-world setting. In addition, a patient-centered real-time approach will allow for capture of granular data and will minimize patient recall bias, which is important for subjective outcomes such as pain. Patient reported outcome measures will be collected at study enrolment, daily during the 12-week observation period, and at the end of the study period.

The study will be conducted in the United Kingdom (UK). Potential participants will be identified and selected from UK healthcare institutions. Both patients diagnosed with episodic and chronic migraine will be included, with a split of approximately 50% of each group. Participants will be enrolled into the study over a period of approximately 6 months. The total data collection period will be approximately 9 months. Potentially eligible patients will receive briefing materials during a routine in-person consultation, or via email. Interested patients will use a link and a unique ID and PIN to complete a study eligibility screener within the study web application. The screener will consist of a series of demographic and clinical history questions. Participants who successfully complete the eligibility will then be able to proceed to the consent stage. Informed consent will also be provided within the study web application.

Consented participants will be required to complete a series of baseline demographic and clinical questions within a window of 72h from registration. A completion reminder will be sent every 24h until the completion window closes. Each participant will be followed up for 12 weeks. During this period, participants will receive an SMS with a link to the study website at the same time every day. A single click on the phone will take participants to the daily migraine survey. Two custom questions asking about migraine symptom occurrence and rimegepant use in the previous 24h will be presented to every participant daily from Day 1 to Day 84. A series of custom follow-up questions, asking further information about any migraine symptoms and related treatment, will be presented based on participant responses to questions 1 and 2 . A completion window of four days (96h) will be allowed for the daily questions. In case participants are still experiencing some migraine symptoms when prompted, they will be able to save their responses and return at a later time within the completion window. On Days 0, 28, 56 and 84 of follow-up, a menstruation question will be presented to all participants. At the end of the 12-week follow-up, the mTOQ-6 Likert version and the TSQM-II questionnaire will be presented to all participants.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • Migraine
  • Acute migraine treatment
  • rimegepant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult participants living in the United Kingdom, with a migraine diagnosis confirmed by a healthcare professional, experiencing at least 4 migraine attacks per month, with a current prescription of rimegepant for acute treatment of migraine, and, if receving preventive migraine treatment, must be stable before enrollment. Participants will be excluded if they are currently using rimegepant as preventive migraine treatment, if present other specific neurological conditions, if currently prescribed with drugs that may indude or inhibits CYP3A4, or if they are participating in a migraine-related clinical trial. All participants enrolled must acknowledge their participation in the study informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. UK resident.
  2. At least 18 years of age.
  3. Migraine diagnosis confirmed by healthcare professional.
  4. Current prescription of rimegepant for acute treatment of migraine.
  5. Experienced at least 4 migraine attacks per month prior to study enrolment.
  6. In the case of participants receiving preventive migraine treatment:

    • For oral preventives, the treatment must be "stable" i.e., final dosing regimen has been found.
    • For migraine preventives administered monthly, the participant must have had their most recent treatment within the 3 weeks prior to study enrolment.
    • For migraine preventives administered quarterly, the participant must have had their most recent treatment within the 2 months prior to study enrolment.
    • If the last treatment is not within the stipulated period, participants will be asked to provide the date of the next scheduled treatment, after which the participant may be invited back to enrol into the study.
  7. Evidence of a personally signed (or acknowledged if obtained electronically or online) and dated document indicating that the participant has been informed of all pertinent aspects of the study.

Exclusion criteria

Exclusion criteria

  1. Current use of rimegepant as a preventive migraine medication.
  2. Current diagnosis of any of the following conditions:

    • new daily persistent headache
    • chronic daily headache
    • cluster headache
    • post-traumatic headache
    • hemicrania continua
    • major depression
    • pain syndromes other than migraine (e.g. fibromyalgia)
    • psychiatric conditions (e.g., schizophrenia)
    • dementia
    • significant neurological disorders other than migraine.
  3. Current prescription of any of the following medications:

    • Strong inhibitors of
    • Strong or moderate inducers of CYP3A4
  4. Patients participating in a migraine-related clinical trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (actual)
Patient registry
No

Groups and cohorts

  • Rimegepant users

    Participants with current prescription of rimegepant for acute treatment of migraine

    Drug: Rimegepant for acute migraine treatment

  • Rimegepant-treated attacks

    Migraine attacks treated with rimegepant

    Drug: Rimegepant for acute migraine treatment

Interventions

  • DrugRimegepant for acute migraine treatment

    Rimegepant for acute migraine treatment

06

What researchers measure

Primary outcomes

  1. Time to Meaninful Pain Relief (MPR) post-dosing

    Proportion of rimegepant-treated attacks with reported MPR: within 1 hour post dose; 1-2 hours post dose; Over 2 hours up to 4 hours post dose; More than 4 hours post dose; who have not achieved MPR and took the medication more than 2 hours before completing the survey; who have not achieved MPR and took the medication less than 2 hours before completing the survey

    Time frame: Daily (within 24hs post dose)

Secondary outcomes

  1. Time to improvement in non-pain symptoms post-dosing

    Proportion of rimegepant-treated attacks with reported improvement in any non-pain symptoms: within 1 hour post dose; 1-2 hours post dose; Over 2 hours up to 4 hours post dose; More than 4 hours post dose; who have not had a meaninful improvement and took the medication more than 2 hours before completing the survey; who have not had a meaninful improvement and took the medication less than 2 hours before completing the survey.

    Time frame: Daily (within 24hs post dose)

  2. Acute migraine treatment optmization

    Proportion of participants who reported treatment optimization using mTOQ6 questionnaire. Treatment optimization is categorized into: very poor treatment optimization, poor treatment optimization, moderate treatment optimization, maximum treatment optimization

    Time frame: 12 weeks follow up

  3. Acute migraine treatment optmization

    Treatment satisfaction assessed using TSQM-II questionnaire. Domain scores (0-100) is presented for the following domains: effectiveness, Side effects, Convenience, and global satisfaction. Higher scores indicate greater satisfaction. Scores are reported separately for each domain.

    Time frame: 12 weeks follow up

07

Study locations

1 site
  • Pfizer
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Oct 2026, 11 months.

Of 160 observational studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2025
First posted
Mar 27, 2025
StartActual
Nov 15, 2025
Primary completionActual
Oct 24, 2026
CompletionActual
Oct 24, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 19, 2026
Primary completion
Oct 31, 2026→Oct 24, 2026 (actual)
Nov 19, 2026
Study completion
Oct 31, 2026→Oct 24, 2026 (actual)
Nov 19, 2026
Show all 2 updates
  1. Nov 19, 2026
    Active, not recruiting→Completed
    Primary completion Oct 31, 2026→Oct 24, 2026 (now actual)
    Study completion Oct 31, 2026→Oct 24, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 29, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06898047
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 27, 2025
Start date
Nov 15, 2025
Primary completion
Oct 24, 2026
Completion
Oct 24, 2026
Last update
Nov 19, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion